Arvinas (ARVN) Total Current Liabilities (2017 - 2026)
Arvinas (ARVN) posted quarterly Total Current Liabilities of $115.9 million for Q1 2026, down 45.84% year-over-year from $214.0 million in Q1 2025, and down 18.67% quarter-over-quarter from $142.5 million in Q4 2025.
Arvinas (ARVN) Total Current Liabilities (2017 - 2026) Analysis & Trends
Arvinas' Total Current Liabilities history runs 10 years deep, the most recent figure standing at $115.9 million for Q1 2026.
- In Q1 2026, Total Current Liabilities fell 45.84% year-over-year to $115.9 million; the TTM figure through Mar 2026 stood at $115.9 million (down 45.84% YoY), while the FY2025 annual figure was $142.5 million, down 37.99% from the prior year.
- Total Current Liabilities for Q1 2026 stood at $115.9 million, down from $142.5 million in the prior quarter.
- The five-year high for Total Current Liabilities was $347.2 million in Q2 2024, with the low at $115.9 million in Q1 2026.
- The 5-year median for Total Current Liabilities is $240.8 million (2024), against an average of $238.2 million.
- The sharpest annual moves came in 2022 and 2025: Total Current Liabilities soared 489.52% in 2022, then slumped 54.55% in 2025.
- Arvinas' Total Current Liabilities stood at $295.1 million in 2022, then declined by 12.88% to $257.1 million in 2023, then declined by 10.62% to $229.8 million in 2024, then tumbled by 37.99% to $142.5 million in 2025, then declined by 18.67% to $115.9 million in 2026.
- Business Quant data shows ARVN's Total Current Liabilities at $115.9 million in Q1 2026, $142.5 million in Q4 2025, and $144.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Arvinas | 585.74 Mn | 17.84 Mn | - | 82.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 82.50 Mn |
| Mar 31, 2026 | 115.90 Mn |
| Dec 31, 2025 | 142.50 Mn |
| Sep 30, 2025 | 144.90 Mn |
| Jun 30, 2025 | 157.80 Mn |
| Mar 31, 2025 | 214.00 Mn |
| Dec 31, 2024 | 229.80 Mn |
| Sep 30, 2024 | 275.90 Mn |
| Jun 30, 2024 | 347.20 Mn |
| Mar 31, 2024 | 240.80 Mn |
| Dec 31, 2023 | 257.10 Mn |
| Sep 30, 2023 | 317.30 Mn |
| Jun 30, 2023 | 306.90 Mn |
| Mar 31, 2023 | 282.90 Mn |
| Dec 31, 2022 | 295.10 Mn |
| Sep 30, 2022 | 244.60 Mn |
| Jun 30, 2022 | 238.20 Mn |
| Mar 31, 2022 | 238.00 Mn |
| Dec 31, 2021 | 261.70 Mn |
| Sep 30, 2021 | 182.51 Mn |